PE20090765A1 - Metodos y composiciones para inducir la apoptosis en celulas cancerosas - Google Patents

Metodos y composiciones para inducir la apoptosis en celulas cancerosas

Info

Publication number
PE20090765A1
PE20090765A1 PE2008000970A PE2008000970A PE20090765A1 PE 20090765 A1 PE20090765 A1 PE 20090765A1 PE 2008000970 A PE2008000970 A PE 2008000970A PE 2008000970 A PE2008000970 A PE 2008000970A PE 20090765 A1 PE20090765 A1 PE 20090765A1
Authority
PE
Peru
Prior art keywords
seq
antibody
amino acid
cancer cells
compositions
Prior art date
Application number
PE2008000970A
Other languages
English (en)
Inventor
Peter Flynn
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of PE20090765A1 publication Critical patent/PE20090765A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

REFERIDO A UN ANTICUERPO O FRAGMENTO FAB`, QUE SE ENLAZA AL RECEPTOR DE MUERTE 5 (DR5), Y QUE INDUCEN LA APOPTOSIS DE CELULAS CANCEROSAS, DICHO ANTICUERPO POSEE: A) UNA REGION VARIABLE DE CADENA PESADA QUE COMPRENDE UN SEGMENTO V POR LO MENOS 90% IDENTICA A LA SEC ID NO:44, UN CDR3 QUE COMPRENDE LA SECUENCIA AMINOACIDA HEEGI (SEC ID NO: 49); Y UN FR4 QUE ES UNA LINEA GERMINAL HUMANA JH4 Y B) UNA REGION VARIABLE DE CADENA LIGERA QUE COMPRENDE UN SEGMENTO V POR LO MENOS 90% IDENTICO A LA SEC ID NO: 46 O SEC ID NO:48, UN CDR3 QUE COMPRENDE LA SECUENCIA AMINOACIDA QXHXXTP (SEC ID NO:50), EN DONDE X REPRESENTA CUALQUIER AMINOACIDO Y UN FR4 QUE ES UNA LINEA GERMINAL HUMANA JK2. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE DICHO ANTICUERPO. SIENDO UTIL PARA EL TRATAMIENTO DE DESORDENES HIPERPROLIFERATIVOS QUE INCLUYEN CANCER TAL COMO: CARCINOMAS, GLIOMAS, MESOTELIOMAS, MELANOMAS, LINFOMAS, LEUCEMIAS
PE2008000970A 2007-06-08 2008-06-06 Metodos y composiciones para inducir la apoptosis en celulas cancerosas PE20090765A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94286207P 2007-06-08 2007-06-08

Publications (1)

Publication Number Publication Date
PE20090765A1 true PE20090765A1 (es) 2009-07-10

Family

ID=39730803

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000970A PE20090765A1 (es) 2007-06-08 2008-06-06 Metodos y composiciones para inducir la apoptosis en celulas cancerosas

Country Status (4)

Country Link
AR (1) AR066913A1 (es)
PE (1) PE20090765A1 (es)
TW (1) TW200911835A (es)
WO (1) WO2008154439A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG188224A1 (en) 2010-08-27 2013-04-30 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
CA2865530C (en) 2012-02-29 2019-02-19 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9
SG10201610788VA (en) 2012-02-29 2017-03-30 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
CN106397594B (zh) * 2016-10-25 2019-06-04 中国药科大学 一种全人源的抗人死亡受体5的激动剂单链抗体及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
TWI318983B (en) * 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
AU2002368077B2 (en) * 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
RU2379056C2 (ru) * 2002-11-27 2010-01-20 Айрм Ллс Способы и композиции для индукции апоптоза раковых клеток
CA2553692C (en) * 2004-01-20 2014-10-07 Kalobios, Inc. Antibody specificity transfer using minimal essential binding determinants
KR20070010046A (ko) * 2004-04-06 2007-01-19 제넨테크, 인크. Ｄｒ5 항체 및 그의 용도

Also Published As

Publication number Publication date
TW200911835A (en) 2009-03-16
AR066913A1 (es) 2009-09-23
WO2008154439A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
CY1118691T1 (el) Συνθεσεις και μεθοδοι χρησης για αντισωματα κατα σκληροστινης
CY1117563T1 (el) Αντισωματα κατα her3 και χρησεις αυτων
MX2009002054A (es) Metodos para inhibir angiogenesis y tratamiento contra enfermedades asociadas con angiogenesis.
AR117913A2 (es) Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
CL2008000789A1 (es) Compuestos derivados de adenina; composicion farmaceutica que comprende a dichos compuestos, utiles para tratar enfermedades alergicas, virales o cancer, entre otras.
CO6280500A2 (es) Anticuerpos humanizados especificos pare l factor von willebrand
PE20150212A1 (es) Anticuerpos anti-trka con propiedades inhibitorias mejoradas y sus derivados
PE20140247A1 (es) Anticuerpos anti-cd38
EA201300242A1 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
CY1120536T1 (el) Μεθοδος και συνθεσεις για τη θεραπευτικη αγωγη του καρκινου
PE20141166A1 (es) Anticuerpos anti-angptl3 y usos de los mismos
CY1115639T1 (el) Διειδικα αγωνιστικα αντισωματα υποδοχεα θανατου
BRPI0513310A (pt) análogos de tetrapeptìdeo
CL2008003788A1 (es) Composicion farmaceutico que comprende a) el anticuerpo b-ly1 humanizado (anti-cd20/antigeno de referenciacion restringida del linfocito b humano/bp35, de tipo ii), b) opcionalmente de 0,001% al 1%p/v de por lo menos un surfactante, y c) de 1 a 100 mm de un tampon; uso para tratar enfermedades relacionadas con cd20.
CO6231039A2 (es) Composiciones que comprenden anticuerpo que se fija al dominio ii de her2 y sus variantes acidas
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
CY1112889T1 (el) Αναλογα αζετιδινης αναστολεων νουκλεοσιδασης και φωσφορυλασης
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
EA201001639A1 (ru) Композиции и способы их получения и применения
UY28757A1 (es) Compuestos de pirazolina substituidos, su preparación y su uso como medicamentos
PE20091655A1 (es) Farmaco para el cancer de higado
PE20121397A1 (es) Anticuerpos especificos para cadherina-17
AR062268A1 (es) Agentes ligantes direccionados dirigidos a pdgfr-alfa y sus usos
DOP2002000545A (es) Moléculas pequeñas para el tratamiento del crecimiento celular anormal
ECSP088821A (es) Derivados de tioxantina y su uso como inhibidores de la mpo

Legal Events

Date Code Title Description
FA Abandonment or withdrawal